Loading stock data…
RMD
$205.02-8.79 (-4.11%)
Market ClosedLast close May 1
ResMed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ResMed Inc. in the Healthcare sector is trading at $205.02. The stock is currently near its 52-week low of $198.64, remaining 19.6% below its 200-day moving average. Technical signals show oversold RSI of 21 and bearish MACD signal, explaining why RMD maintains its current current market pressure. The Whystock Score of 80/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 21) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$205.02
Potential Upside
3.2%
Whystock Fair Value$211.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$273.40+33.4%
Range$180.00 – $340.00
Fundamentals
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.73
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Strong income play. Yield provides a meaningful total return floor.
108.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.16%
Volume
Today's trading volume
2.83M
Recent News
Why ResMed (RMD) Narrative Is Shifting As Analysts Reassess Growth And Valuation Assumptions
ResMed’s fair value estimate has been trimmed from US$296.53 to US$288.21, a reduction of about 2.8% that signals a more cautious stance on what analysts are willing to pay for the shares. This shift lines up with recent research where some firms have cut price targets by US$5 to US$45, while others still see room to build exposure based on their own assumptions. As you read on, you will see how to interpret these mixed signals and keep track of how the story around ResMed is...
2 Cash-Heavy Stocks with Exciting Potential and 1 We Turn Down
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
ResMed Q3 Earnings Call Highlights
ResMed (NYSE:RMD) reported third-quarter fiscal 2026 results highlighted by revenue growth, gross margin expansion, and higher non-GAAP earnings per share, while also announcing a CFO transition and a planned tuck-in acquisition to expand beyond its core sleep apnea business. Leadership updates: CF
RMD Q1 Deep Dive: Mask Portfolio Drives Growth Amid Market Uncertainty and New CFO Appointment
Medical device company ResMed (NYSE:RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 10.8% year on year to $1.43 billion. Its non-GAAP profit of $2.86 per share was 2.2% above analysts’ consensus estimates.
RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
Resmed beats Q3 earnings and revenue estimates with strong margin gains, yet shares slip post earnings despite growth across key segments.